Trends in the nootropic drugs market in the republic of Uzbekistan
DOI:
https://doi.org/10.24959/sphhcj.25.353Keywords:
nootropic drugs; drug market; import; production; pharmaceutical market; Uzbekistan; marketing analysis.Abstract
The increasing incidence of cerebrovascular and cognitive disorders in Uzbekistan, driven by a growing information load and an aging population, has led to a heightened demand for effective nootropic medications. The pharmaceutical market is adapting to this demand through a diversified range of drugs, including both imported and domestically produced products.
Aim. This study aims to evaluate the dynamics of the nootropic drug market in the Republic of Uzbekistan from 2015 to 2024 in both physical and monetary terms, including the analysis of import volumes, domestic production, key market players, dosage forms, and trends in international nonproprietary names.
Materials and methods. The study utilized aggregated data on the registration, import, and production of nootropic drugs classified under ATC group N06BX. Marketing analysis methods and qualimetric tools were applied to identify quantitative trends, structural shifts over the study period.
Results and discussion. The article presents an analysis of the dynamics of the nootropic drug market in the Republic of Uzbekistan over the period 2015–2024. It examines quantitative changes in both physical and monetary terms, as well as the structure of imports and domestic production. Key trends are identified, including an increase in nootropic consumption up to 2022 followed by a subsequent decline, the strengthening of domestic manufacturers' positions, and changes in the assortment and consumption structure by international nonproprietary names. A comparative analysis of supplies from CIS and non-CIS countries is provided, along with an evaluation of the activity of leading domestic companies. Particular attention is given to dosage forms. The findings of the study may be used to assess the current state of the pharmaceutical market and to inform strategic planning for the development of the nootropic drug sector in Uzbekistan.
Conclusions The nootropic drug market in Uzbekistan shows cyclical dynamics with strong domestic development potential. Market fluctuations reflect clinical guideline revisions and increased emphasis on evidence-based prescribing. The study highlights the growing role of local manufacturers and the shift toward more complex and effective nootropic formulations.
References
Umarova, Sh. Z., & Sultanbaeva, N. M. U. (2021). Optimization of systemic pharmaceutical care for patients with cardiovascular diseases: monograph.
Saydalieva, D. U., Sultanbaeva, N. M. U., & Umarova, Sh. Z. (2023). Assortment analysis of nootropic drugs registered in the Republic of Uzbekistan for 2018-2022. Journal of Pharmacy Pharmacology, (3), 59–65.
Vahith, E., Balakrishnan, A., Ramaswamy, V., & Natesan, S. (2024). Stability-Indicating RP-HPLC Method Development and Validation for Simultaneous estimation of Cinnarizine and Piracetam bulk and in Capsule dosage form. African Journal of Biomedical Research, 27(3), 362–369.
Patel, J., King, A., Malempati, M., & Patel, M. (2024). Understanding nootropics and cognitive enhancement: mechanism of action and ethical considerations. Health Open Research, (6), 2.
Belyaeva, P. S., Klimenko, P. Yu., Kosogorova, N. L., Rusanovsky, V. V., & Akimov, A. A. (2024). On the use of nootropic drugs in the correction of intellectual disabilities in children. Youth Innovation Bulletin, 13(1), 207–209.
Maan, P., Gupta, N., & Chauhan, S. (2025). Nootropics: Traditional Medicinal Prospective. In Neuro-Nutraceuticals and Drug Discovery and Delivery in Alzheimer’s Disease (pp. 235–268). Apple Academic Press.
Bradley, M. (2024). Nootropic effects of herbal medicines: a brief introduction. Australasian College of Nutritional Environmental Medicine Journal, 43(2), 6.
Saydalieva, D. U., & Sultanbaeva, N. M. U. (2023). XYZ analysis of nootropic drugs in the Republic of Uzbekistan for 2018-2022. Journal of Pharmacy pharmacology, (4), 82–86.
Petersen, R. C., Lopez, O., Armstrong, M. J., Getchius, T. S. D., Ganguli, M., Gloss, D., Gronseth, G. S., Marson, D., Pringsheim, T., Day, G. S., Sager, M., Stevens, J., & Rae-Grant, A. (2018). Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(3), 126–135. https://doi.org/10.1212/WNL.0000000000004826
Dementia: Assessment, management and support for people living with dementia and their carers. (2018). National Institute for Health and Care Excellence (NICE).
Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. The Cochrane database of systematic reviews, (1), CD003120. https://doi.org/10.1002/14651858.CD003120.pub3.
Shishkova, V. N., Adasheva, T. V. (2021). Chronic cerebral ischemia and headache in patients in primary care physician's practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 13(1):131-137. https://doi.org/10.14412/2074-2711-2021-1-131-137
You, T., Wang, Y., Chen, S., Dong, Q., Yu, J., & Cui, M. (2024). Vascular cognitive impairment: Advances in clinical research and management. Chinese medical journal, 137(23), 2793–2807. https://doi.org/10.1097/CM9.0000000000003220
Wheeler, S., & Acord-Vira, A. (2023). Occupational Therapy Practice Guidelines for Adults With Traumatic Brain Injury. The American journal of occupational therapy : official publication of the American Occupational Therapy Association, 77(4), 7704397010. https://doi.org/10.5014/ajot.2023.077401
Order of the Ministry of Health of the Republic of Uzbekistan "On improving standards for the diagnosis and treatment of neurological diseases in adults" No. 154 (2018, March 20).
Order of the Ministry of Health of the Republic of Uzbekistan "On the implementation of clinical protocols for the diagnosis and treatment of speech and developmental disorders in children" No. 360 (2021, Jule 12).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
